Sanofi Touts Sarclisa’s Late-Bloomer Status In Frontline Myeloma

Sarclisa has looked like an also-ran alongside J&J and Genmab’s Darzalex, but Sanofi’s drug could start to shine thanks to new first-line trial results

Multiple myeloma
An electron microscope rendering of multiple myeloma cells. • Source: Shutterstock

When Sarclisa was launched back in 2020, Sanofi hailed the multiple myeloma therapy as its return to oncology, but since then it has barely troubled its main rival, J&J and Genmab’s multi-billion blockbuster Darzalex.

More from Business

More from Scrip